Antifungal use as a proportion of admissions (n=30 020)
| Disease | Amphotericin B (%) | Andulafungin (%) | Caspofungin (%) | Fluconazole (%) | Itraconazole (%) | Liposomal amphotericin B (%) | Micafungin (%) | Posaconazole (%) | Voriconazole (%) |
|---|---|---|---|---|---|---|---|---|---|
| 1. Aspergillosis | 2 | * | 10 | 6 | 37 | 22 | 5 | 7 | 33 |
| 2. Candidosis | 0 | 0 | 8 | 89 | 1 | 4 | 1 | * | 2 |
| 3. Other confirmed fungal infection | * | * | * | * | 0 | 89 | * | * | |
| 4. Stem cell/bone marrow transplant in haematological malignancy | 15 | 56 | 33 | 11 | 4 | 6 | |||
| 5. Haematological malignancy | 0 | * | 5 | 71 | 17 | 7 | * | 3 | 5 |
| 6. Stem cell/bone marrow transplant (no record of haematological malignancy) | * | * | 55 | * | * | * | 7 | ||
| 7. Lung transplant | 11 | 10 | 41 | 28 | 10 | 7 | 4 | 16 | |
| 8. Other solid organ transplant | * | 7 | 84 | * | * | 4 | * | 7 | |
| 9. Solid tumour | 0 | 0 | 2 | 97 | 1 | 1 | 0 | * | 0 |
| 11. Immunosystem disease | * | * | 82 | 8 | * | * | * | ||
| 12. Acute peritonitis | * | 18 | 80 | * | 5 | 3 | * | ||
| 13. Abdominal surgery | * | 11 | 88 | * | 2 | * | * | ||
| Total | 0 | 0 | 4 | 75 | 10 | 5 | 0 | 2 | 4 |
*Small numbers are suppressed.